Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Benchmark Downgrades Emergent BioSolutions to Hold

Benchmark Downgrades Emergent BioSolutions to Hold

Benchmark analyst Robert Wasserman downgrades Emergent BioSolutions (NYSE:EBS) from Buy to Hold.

byBenzinga Newsdesk

November 10, 2022

1 minute read

Benchmark analyst Robert Wasserman downgrades Emergent BioSolutions (NYSE:EBS) from Buy to Hold.

Analyst Ratings

6 Analysts Have This to Say About Qualys

By Benzinga Insights

December 2, 2:00 PM

Qualys (NASDAQ:QLYS) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…

QLYS

US Lawmakers Want To Slash Gary Gensler’s Salary From Over $300K To Just $1 — Here’s Why

By Mehab Qureshi

November 6, 11:16 PM

A United States lawmaker is seeking to significantly reduce the salary of Securities and Exchange Commission (SEC) chair Gary Gensler to just $1 per year.

BTC

TSMC Expansion in Japan Gets Financial Lift with ¥2T Government Fund

By Anusuya Lahiri

November 8, 10:29 AM

Japan looks to earmark ¥2 trillion ($13.3 billion) in additional budget to boost its domestic semiconductors manufacturing position.

NVDA

G Willi Announces Appointment By Board Of Directors Of Joseph Williger As New Chief Executive Officer

By Benzinga Newsdesk

January 17, 11:22 AM

G. Willi-Food International Ltd. (NASDAQ:WILC) (the "Company" or "Willi Food"), a global company that specializes in the development, marketing and international distribution of kosher

WILC

Benchmark Downgrades Emergent BioSolutions to Hold

Related Posts

6 Analysts Have This to Say About Qualys

US Lawmakers Want To Slash Gary Gensler’s Salary From Over $300K To Just $1 — Here’s Why

TSMC Expansion in Japan Gets Financial Lift with ¥2T Government Fund

G Willi Announces Appointment By Board Of Directors Of Joseph Williger As New Chief Executive Officer